BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pezzicoli G, Filoni E, Gernone A, Cosmai L, Rizzo M, Porta C. Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? - ie Strategies to Revert Resistance to mTOR Inhibitors. Cancer Manag Res 2021;13:7623-36. [PMID: 34675658 DOI: 10.2147/CMAR.S267220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Raskov H, Gaggar S, Tajik A, Orhan A, Gögenur I. Metabolic switch in cancer - Survival of the fittest. Eur J Cancer 2023;180:30-51. [PMID: 36527974 DOI: 10.1016/j.ejca.2022.11.025] [Reference Citation Analysis]
2 Danielpour D, Corum S, Leahy P, Bangalore A. Jagged-1 is induced by mTOR inhibitors in renal cancer cells through an Akt/ALK5/Smad4-dependent mechanism. Current Research in Pharmacology and Drug Discovery 2022;3:100117. [DOI: 10.1016/j.crphar.2022.100117] [Reference Citation Analysis]